Delivery Order SPE2DB25D3005-SPE2DB25FQJSV
- Not listed
- The Defense Logistics Agency awarded a $10,219.44 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Dupixent 300 mg/2 ml pens. This non-competitive, firm fixed-price delivery order is scheduled for completion by September 16, 2025, with performance at the vendor's Conshohocken, Pennsylvania location. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $62,311 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Dupixent 300 mg/2 mL pens. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, valued at $1 billion through December 2026. The award was competitively awarded with...
- The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran...
- The Defense Logistics Agency awarded a $39,157.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 mL pen injections on September 10, 2025, with completion scheduled for September 11, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was made on a non-set-aside, competitive basis and will be...
- The Defense Logistics Agency awarded a $3,058.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-set-aside competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $10,809.15 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,617.14 by the Defense Logistics Agency on September 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,389.54 to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 6, 2025, with completion expected by August 7, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- SPE2DB25D3005Indefinite Delivery Contract
- SPE2DB25D3005-SPE2DB25FQJSVDelivery Order
The Defense Logistics Agency awarded a $109,981.33 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Dupixent 300 mg/2 mL pens. This firm fixed-price contract, with an ultimate completion date of September 16, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The award was competitively awarded with no set-aside designation, and performance is based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare systems. Dupixent (dupilumab) is a prescription biologic medication used to treat eczema, asthma, and chronic rhinosinusitis, making this delivery order part of the broader pharmaceutical supply chain supporting the Defense Health Agency and other military healthcare programs. The company's extensive portfolio of federal contracts demonstrates its capability to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains, positioning it as a key provider within DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $110.0k | 9/15/25 |